Let's hope so! They are the evt sponsors, of which we have heard nothing. What dose levels have been passed, what data/biomarkers have been acquired? This is all very standard reporting for a company that is informing their shareholders of how trials are progressing. It is very disingenuous, but not surprising, that acceptance of an abstract with no data they think meets one of their self reported milestones of 'interim data'. Get a deal done, get it to a competent team that can move it forward at a rate the patients deserve!
- Forums
- ASX - By Stock
- KZA
- Ann: Acceptance of late-breaking abstract of PNOC022 data
Ann: Acceptance of late-breaking abstract of PNOC022 data, page-3
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online